{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-022423","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.523309+00:00","generated_at":"2026-05-24T23:27:56.022895+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sagimet's second FASN inhibitor TVB-3567 gets IND clearance for acne","bullets":["FDA's Division of Dermatology and Dentistry cleared IND for TVB-3567, a small molecule FASN inhibitor.","TVB-3567 targets sebum production; FASN drives ~80% of sebum lipids in acne pathogenesis.","First-in-human Phase 1 trial planned for 2025, randomized, double-blind, placebo-controlled.","Building on denifanstat data, partner Ascletis showed significant lesion reduction in Phase 2 acne trial.","Over 50 million acne patients in the US; FASN inhibition seen as significant commercial opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-022423","json":"https://secwatch.observer/filing/0001104659-25-022423.json","markdown":"https://secwatch.observer/filing/0001104659-25-022423.md","text":"https://secwatch.observer/filing/0001104659-25-022423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925022423/0001104659-25-022423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925022423/tm258742d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:27:56.022895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}